- 1. PEG Recombinant Human Megakaryocyte Growth and Development Factor
- [A synthetic form of a protein that is normally made in the body to regulate the production of platelets. ( NCI )] (UMLS (NCI) C0533199) =Organic Chemical ;
| - 6. PEG-IL-2
- [A complex of polyethylene glycol conjugated with human recombinant cytokine interleukin-2 (IL-2) with antineoplastic activity. PEG-interleukin-2 induces natural killer (NK) cell activity and the production of interferon-gamma (IFN-gamma), and enhances T cell-mediated cytotoxicity. Pegylation of IL-2 protects the cytokine from degradation. (NCI04) ( NCI )] (UMLS (NCI) C0083036) =Organic Chemical
|
- 2. PEG-ASP/PRED/VCR
- (UMLS (NCI) C0279047) =Therapeutic or Preventive Procedure
| - 7. PEG-Interferon Alfa-2b/Thalidomide
- (UMLS (NCI) C1327835) =Therapeutic or Preventive Procedure; ;
|
- 3. PEG-ASP/VCR
- (UMLS (NCI) C0392954) =Therapeutic or Preventive Procedure
| - 8. PEG-Intron
- (UMLS (NCI) C0939422) =Organic Chemical; Pharmacologic Substance; Immunologic Factor
|
- 4. PEG-IFN Alfa-2b
- [An anticancer drug that belongs to the family of drugs called biological response modifiers. PEG-interferon alfa-2b is a cytokine. Also called SCH 54031. ( NCI )] (UMLS (NCI) C0796545) PEG-IFN-a 2b;
peginterferon alfa-2b;
PEG-Interferon Alfa-2b;
PEGINTERFERON ALPHA-2B;
PEGINTERFERON ALPHA-2B PREPARATION;
Polyethylene Glycol IFN-A2b;
Polyethylene Glycol Interferon Alfa-2b =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor =PEGINTERFERON;
=PEGINTERFERON ALPHA-2B 120 MCG/0.5ML;
PEGINTERFERON ALPHA-2B 150 MCG/0.5ML;
PEGINTERFERON ALPHA-2B 50 MCG/0.5ML;
PEGINTERFERON ALPHA-2B 80 MCG/0.5ML;
| - 9. Pegylated Doxorubicin HCl Liposome
- [A liposome-encapsulated form of the hydrochloride salt of the anthracycline antineoplastic antibiotic doxorubicin. Liposomal delivery of doxorubicin HCL improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects. Doxorubicin intercalates into DNA and interacts with topoisomerase II, consequently inhibiting DNA replication and repair and RNA and protein synthesis. This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=269242&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=269242&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1555" NCI Thesaurus) ( PDQ )] (UMLS (NCI) C1327848) Pegylated Liposomal Doxorubicin Hydrochloride;
=Organic Chemical; Antibiotic ;
|
- 5. PEG-IFN-a
- [A covalent conjugate of recombinant interferon alpha and polyethylene glycol (PEG), used as an antiviral and antineoplastic agent. The biological activity of this agent is derived from its interferon alpha protein moiety. Interferons alfa bind to specific cell-surface receptors, leading to the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects. The PEG moiety lowers the clearance of interferon alpha, thereby extending the duration of its therapeutic effects, but may also reduce interferon-mediated stimulation of an immune response. (NCI04) ( NCI )] (UMLS (NCI) C0907160) PEG-interferon alfa;
Pegylated Interferon Alfa =Organic Chemical; Pharmacologic Substance; Immunologic Factor | - 10. Pegylated Interferon Alfa/Temozolomide
- (UMLS (NCI) C1134526) =Therapeutic or Preventive Procedure
|
home
